Amyris, Inc. (NASDAQ:AMRS) fell 6.9% during trading on Friday . The stock traded as low as $2.82 and last traded at $2.82. 1,523,948 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 2,420,260 shares. The stock had previously closed at $3.03.

Several research firms have recently commented on AMRS. BidaskClub raised Amyris from a “sell” rating to a “hold” rating in a research note on Thursday, September 17th. ValuEngine raised Amyris from a “hold” rating to a “buy” rating in a research note on Tuesday, August 11th. Zacks Investment Research raised Amyris from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 7th. Finally, Oppenheimer reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Amyris in a research note on Friday, September 11th.

The firm has a 50 day moving average of $2.96 and a 200-day moving average of $3.43. The company has a market cap of $577.34 million, a P/E ratio of -1.21 and a beta of 0.53.

Amyris (NASDAQ:AMRS) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.37). The company had revenue of $30.01 million during the quarter, compared to the consensus estimate of $35.76 million. Equities research analysts expect that Amyris, Inc. will post -1.23 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of AMRS. Bank of New York Mellon Corp raised its stake in Amyris by 12.4% during the 1st quarter. Bank of New York Mellon Corp now owns 190,567 shares of the biotechnology company’s stock valued at $487,000 after purchasing an additional 20,974 shares during the period. State Street Corp raised its stake in Amyris by 26.6% during the 1st quarter. State Street Corp now owns 1,115,351 shares of the biotechnology company’s stock valued at $2,855,000 after purchasing an additional 234,634 shares during the period. Victory Capital Management Inc. raised its stake in Amyris by 93.0% during the 1st quarter. Victory Capital Management Inc. now owns 19,837 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 9,558 shares during the period. Citigroup Inc. raised its stake in Amyris by 15.0% during the 1st quarter. Citigroup Inc. now owns 26,532 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 3,456 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in Amyris by 161.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 18,595 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 11,488 shares during the period. 37.80% of the stock is currently owned by institutional investors.

About Amyris (NASDAQ:AMRS)

Amyris, Inc, a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.